Top Qs
Timeline
Chat
Perspective
Sintilimab
Medication to treat Hodgkin's disease From Wikipedia, the free encyclopedia
Remove ads
Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease,[2] and has been approved in China.[3]
 | A major contributor to this article appears to have a close connection with its subject. (December 2021) |
It is a fully human IgG4 monoclonal antibody[4] that binds to programmed cell death protein 1.[5]
It was jointly developed by Innovent Biologics[6] and Eli Lilly.[7]
Remove ads
Medical uses
Sintilimab is medication that is indicated for the treatment of relapsed or refractory classical Hodgkin's lymphoma[8] after failure of at least second-line systemic chemotherapy.[5]
Side effects
Common side effects include fever, thyroid dysfunction, elevation of liver enzymes, and lung inflammation.[9]
Research
Currently, more than 20 clinical trials are ongoing to evaluate the anti-tumor effect of sintilimab injection, either as monotherapy or in combination with other agents, on a variety of solid tumors.[10] In January 2019, the result of the registration trial of sintilimab in people with refractory or relapsed classical Hodgkin's lymphoma was published.[8]
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads